• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4591707)   Today's Articles (1498)   Subscriber (49313)
Number Citation Analysis
1
Short course of EGF receptor tyrosine kinase inhibitor erlotinib (OSI-774) reduces tumor cell proliferation and active MAP kinase in situ in untreated operable breast cancers: A strategy for patient selection into phase II trials with signaling inhibitors. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA